Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3276

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Interventions: Placebo, PF-06823859; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: PF-06821497, Docetaxel, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more

Conditions: Headache Disorders, Dizziness, Vestibular Diseases, Sinus Disease, Vestibular Disorder, Migraine Disorders, Headache, Migraine, Facial Pain
Interventions: Not listed
Lead sponsor: Association of Migraine Disorders; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: North Kingstown, Rhode Island

Conditions: Alopecia Areata
Interventions: Ritlecitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19 Vaccines
Interventions: BNT162b2 Vaccine, Tdap Vaccine; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 (2025/2026 formulation); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 27
States / cities: Palo Alto, California • San Diego, California • Homestead, Florida + 21 more

Conditions: Healthy
Interventions: Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Myeloma
Interventions: Elrantamab, clonoSEQ; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 4,338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more

Conditions: Ulcerative Colitis
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Headache Ear Auditory Dizziness Sinus (HEADS) Registry

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

About this Pfizer sponsor directory page